JAMA Surg: FOLFIRINOX or GA first-line treatment of limited pancreatic catheter adenocarcinoma.

Fluorouresy, calcium zolinalate, Ilitikon, Oshariplatin and Gixithabin combined with yewol are the first-line chemotherapy programs for pancreatic cancerRecently, researchers compared or first-line treatment of limited pancreatic catheter adenocarcinoma efficacyPatients with previously untreated limited pancreatic catheter adenocarcinoma participated in the study in which patients received at least one cycle or treatment of the groupThe main endpoints of the study were excision rate, imaging indicators (reaction assessment criteria for solid tumors), serological indicators (serum cancer antigen levels), and total survival rates after chemotherapyMale name in the patientPatients receiving treatment had a lighter median age: older and higher rates of points or below had greater aggressive tumorsThe adjusted study found that the difference between the or the patient's objective serological and radiological response indicators was not significant, but the proportion of patients in the treatment group (in patients in case) achieved partial reactions was higher than in the only cases in the groupThe proportion of patients receiving radiotherapy in the group was higher, but the overall survival risk ratio of patients with both options was similarThe study concluded that the total survival rate of patients with limited pancreatic cancer received or used as a first-line chemotherapy regimen was similar, but the group response rate and pancreatic excision rate were higher